Assignee
GENFIT
FR·61 granted patents·37 pending applications·244 citations·filing 2001–2025
Top patents by PatentIndex Score
98 records- 0198US11857523B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Jan 2, 2024·7 cites·9 claims
- 0298US11850223B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Dec 26, 2023·7 cites·10 claims
- 0398US11331292B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2020·Granted May 17, 2022·13 cites·11 claims
- 0497US12295928B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 13, 2025·2 cites·26 claims
- 0597US12053445B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2021·Granted Aug 6, 2024·7 cites·11 claims
- 0696US12310935B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 27, 2025·1 cites·28 claims
- 0796US12303480B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 20, 2025·1 cites·15 claims
- 0896US12295927B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 13, 2025·1 cites·26 claims
- 0996US12290498B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted May 6, 2025·1 cites·14 claims
- 1096US12233038B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2023·Granted Feb 25, 2025·1 cites·24 claims
- 1195US7566737B2Combinations of substituted 1,3-diphenylprop-2-en-1-one derivatives with other therapeutically active ingredientsGENFIT·Filed 2006·Granted Jul 28, 2009·23 cites·9 claims
- 1294US11974997B2RORgamma modulators and uses thereofGENFIT·Filed 2021·Granted May 7, 2024·7 cites·14 claims
- 1393US12053456B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2021·Granted Aug 6, 2024·3 cites·9 claims
- 1493US11185519B2Methods of treatment of cholestatic diseasesGENFIT·Filed 2017·Granted Nov 30, 2021·15 cites·10 claims
- 1593US9221751B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Dec 29, 2015·9 cites·21 claims
- 1692US11590108B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Feb 28, 2023·9 cites·8 claims
- 1791US11478440B2Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agentGENFIT·Filed 2018·Granted Oct 25, 2022·10 cites·3 claims
- 1891US9585853B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2015·Granted Mar 7, 2017·4 cites·15 claims
- 1990US9782373B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Oct 10, 2017·3 cites·6 claims
- 2088US10350181B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2018·Granted Jul 16, 2019·2 cites·19 claims
- 2186US11484517B2Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitorGENFIT·Filed 2018·Granted Nov 1, 2022·10 cites·2 claims
- 2286US10653678B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Granted May 19, 2020·3 cites·6 claims
- 2386US8895619B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2014·Granted Nov 25, 2014·8 cites·11 claims
- 2486US2025281437A1Methods of treatment of cholestatic diseasesGENFIT·Filed 2025·Application pending·0 cites
- 2585US11052092B2N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseasesGENFIT·Filed 2018·Granted Jul 6, 2021·3 cites·16 claims
- 2685US11033534B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Jun 15, 2021·3 cites·10 claims
- 2784US7547729B21,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of sameGENFIT·Filed 2005·Granted Jun 16, 2009·9 cites·6 claims
- 2883US7375135B2Fatty acid derivatives; preparation and uses thereofGENFIT·Filed 2002·Granted May 20, 2008·39 cites·43 claims
- 2982US11400078B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2020·Granted Aug 2, 2022·1 cites·6 claims
- 3080US10905680B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Granted Feb 2, 2021·1 cites·18 claims
- 3179US12208087B2Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammationGENFIT·Filed 2020·Granted Jan 28, 2025·1 cites·10 claims
- 3279US7385082B2Preparation of 1,3-diphenylprop-2-en-1-one derivativesGENFIT·Filed 2004·Granted Jun 10, 2008·10 cites·15 claims
- 3378US10130613B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·10 claims
- 3478US10130612B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 20, 2018·1 cites·11 claims
- 3578US10117856B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·10 claims
- 3678US10117855B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2017·Granted Nov 6, 2018·1 cites·14 claims
- 3778US9902725B2Heterocyclic derivatives as RORgamma modulatorsGENFIT·Filed 2015·Granted Feb 27, 2018·4 cites·19 claims
- 3876US7632870B2Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereofGENFIT·Filed 2003·Granted Dec 15, 2009·8 cites·11 claims
- 3974US7943661B2Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereofGENFIT·Filed 2003·Granted May 17, 2011·7 cites·17 claims
- 4074US2024410010A1Non-invasive diagnostic of non-alcoholic steatohepatitisGENFIT·Filed 2024·Application pending·0 cites
- 4173US11103484B2Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2020·Granted Aug 31, 2021·0 cites·8 claims
- 4272US11676269B2Automated pattern recognition and scoring method of histological imagesGENFIT·Filed 2018·Granted Jun 13, 2023·3 cites·10 claims
- 4372US11191749B2Pharmaceutical compositions for combination therapyGENFIT·Filed 2018·Granted Dec 7, 2021·1 cites·8 claims
- 4470US2025118449A1Systems and methods for patient classificationGENFIT·Filed 2023·Application pending·0 cites
- 4569US10022343B2Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersGENFIT·Filed 2017·Granted Jul 17, 2018·0 cites·10 claims
- 4666US9115073B21,3-diphenylpropane derivatives, preparations and uses thereofGENFIT·Filed 2012·Granted Aug 25, 2015·2 cites·18 claims
- 4765US2019000813A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2018·Application pending·0 cites
- 4865US2022323422A1Methods of treatment for cholestatic and fibrotic diseasesGENFIT·Filed 2022·Application pending·0 cites
- 4963US10792277B2Methods of treatment of fibrosis and cancersGENFIT·Filed 2017·Granted Oct 6, 2020·0 cites·23 claims
- 5061US7253296B2Acylated aminopropanediols and analogues and therapeutic uses thereofGENFIT·Filed 2004·Granted Aug 7, 2007·1 cites·33 claims
Showing the top 50 of 98 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →